奥马珠单抗治疗中重度过敏性哮喘的临床应用进展
Clinical Application of Omazumab in the Treatment of Moderate and Severe Allergic Asthma
DOI: 10.12677/ACM.2023.1371540, PDF,   
作者: 卡米拉·艾合曼提*：新疆医科大学第一附属医院儿科学院，新疆 乌鲁木齐；茹 凉#：新疆医科大学第一附属医院儿内二科，新疆 乌鲁木齐
关键词: 奥马珠单抗；过敏性哮喘；Omalizumab； Allergic Asthma
摘要: 近年来，过敏性哮喘在全球范围内的患病率仍持续上升，严重影响着哮喘患者的身心健康。IgE的增长是过敏性哮喘症状持续和恶化的重要因素，促进IgE活性的降低，可以从根源上阻断过敏性哮喘发作的炎症级联反应。奥马珠单抗作为第一个抗IgE人源化单克隆抗体，其通过抑制IgE引导的变态反应，在中重度过敏性哮喘治疗中的有效性及安全性已得到证实，开创了哮喘生物靶向药物治疗的新领域。本文旨在论述近年来国内外奥马珠单抗在中重度过敏性哮喘治疗中的临床应用进展，评价其有效性及安全性，并对多项临床检验指标与奥马珠单抗治疗疗效之间的关系做一综述。
Abstract: In recent years, the prevalence of allergic asthma continues to rise worldwide, which seriously af-fects the physical and mental health of asthmatic patients. The increase of IgE is an important factor in the persistence and deterioration of allergic asthma symptoms, and promoting the decrease of IgE activity can block the inflammatory cascade of allergic asthma attack from the root. Omazumab, as the first anti-IGE humanized monoclonal antibody, has been proven to be effective and safe in the treatment of moderate-to-severe allergic asthma by inhibiting IgE induced allergic reactions, cre-ating a new field of biological targeted drug therapy for asthma. This article aims to review the clin-ical application of omalizumab in the treatment of moderate to severe allergicasthma in recent years, evaluate its efficacy and safety, and review the relationship between a number of clinical in-dicators and the therapeutic effect of omalizumab.
文章引用：卡米拉·艾合曼提, 茹凉. 奥马珠单抗治疗中重度过敏性哮喘的临床应用进展[J]. 临床医学进展, 2023, 13(7): 11043-11049. https://doi.org/10.12677/ACM.2023.1371540

参考文献

[1] 聂远航. 真实世界奥马珠单抗治疗中重度过敏性哮喘的临床观察[D]: [硕士学位论文]. 汕头: 汕头大学, 2021.
[2] 国家呼吸系统疾病临床医学研究中心, 中华医学会儿科学分会呼吸学组哮喘协作组, 中国医药教育协会儿科专业委员会, 等. 奥马珠单抗在儿童过敏性哮喘临床应用专家共识[J]. 中华实用儿科临床杂志, 2021, 36(12): 881-890. [Google Scholar] [CrossRef] 
[3] 中华医学会变态反应分会呼吸过敏学组(筹), 中华医学会呼吸病学分会哮喘学组. 中国过敏性哮喘诊治指南(第一版, 2019年) [J]. 中华内科杂志, 2019, 58(9): 636-655.
[4] Global Initiative for Asthma (2020) Global Strategy for Asthma Management and Prevention. http://ginasthma.org
[5] 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2020年版) [J]. 中华结核和呼吸杂志, 2020, 43(12): 1023-1048. [Google Scholar] [CrossRef] [PubMed]
[6] 邢斌. 重症哮喘诊断与处理中国专家共识[J]. 中华结核和呼吸杂志, 2017, 40(11): 813-829.
[7] Oliveria, J.P., Agayby, R. and Ganweau, G.M. (2021) Regulatory and IgE+ B Cells in Allergic Asthma. In: Mion, F. and Tonon, S., Eds., Regula-tory B Cells, Humana, New York, 375-418. [Google Scholar] [CrossRef] [PubMed]
[8] Tan, R., Liew, M.F., Lim, H.F., Leung, B.P. and Wong, W.S.F. (2020) Promises and Challenges of Biologics for Severe Asthma. Bio-chemical Pharmacology, 179, Article ID: 114012. [Google Scholar] [CrossRef] [PubMed]
[9] Tenero, L., Rossignoli, S. and Piacentini, G. (2020) Severe Asthma: When to Resort to Biological Agents. Pediatric Allergy and Immunology, 31, 37-39. [Google Scholar] [CrossRef] [PubMed]
[10] Loureiro, C.C., Amaral, L., Ferreira, J.A., et al. (2018) Omalizumab for Severe Asthma: Beyond Allergic Asthma. BioMed Research International, 2018, Article ID: 3254094. [Google Scholar] [CrossRef] [PubMed]
[11] Zhao, Z.T., Ji, C.M., Yu, W.J., et al. (2016) Omalizumab for the Treatment of Chronic Spontaneous Urticaria: A Meta-Analysis of Randomized Clinical Trials. Journal of Allergy and Clinical Immunology, 137, 1742-1750.E4. [Google Scholar] [CrossRef] [PubMed]
[12] Licari, A., Marseglia, G., Castagnoli, R., Marseglia, A. and Ciprandi, G. (2015) The Discovery and Development of Omalizumab for the Treatment of Asthma. Expert Opinion on Drug Discovery, 10, 1033-1042. [Google Scholar] [CrossRef] [PubMed]
[13] Navines-Fetter, A., Serrano-Candelas, E., Molina-Molina, G.J. and Martín, M. (2016) IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. Journal of Immunology Re-search, 2016, Article ID: 8163803. [Google Scholar] [CrossRef] [PubMed]
[14] Lovinsky-Desir, S. (2020) The Use of Biologic Therapies for the Management of Pediatric Asthma. Pediatric Pulmonology, 55, 803-808. [Google Scholar] [CrossRef] [PubMed]
[15] Balbino, B., Herviou, P., Godon, O., et al. (2020) The Anti-IgE mAb Omalizumab Induces Adverse Reactions by Engaging Fcγ Receptors. Journal of Clinical Investigation, 130, 1330-1335. [Google Scholar] [CrossRef] 
[16] 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识(2021版)[J]. 中华结核和呼吸杂志, 2022, 45(4): 341-354. [Google Scholar] [CrossRef] [PubMed]
[17] Asano, K., Sumi, K., Yoshisue, H., et al. (2020) Real-Life Safety and Efficacy of Omalizumab in Japanese Patients with Severe Allergic Asthma Who Were Subjected to Dosing Table Revision or Expansion: A Post-Marketing Surveillance. Pulmonary Pharmacology & Therapeutics, 64, Article ID: 101950. [Google Scholar] [CrossRef] [PubMed]
[18] Humbert, M., Taille, C., Mala, L., et al. (2018) Omalizumab Effec-tiveness in Patients with Severeallergic Asthma according to Blood Eosinophil Count: The STELLAIR Study. European Respiratory Journal, 51, Article ID: 1702523. [Google Scholar] [CrossRef] [PubMed]
[19] Mansur, A.H., Srivastava, S., Mitchell, V., Sullivan, J. and Kasujee, I. (2017) Longterm Clinical Outcomes of Omalizumab Therapy in Severe Allergic Asthma: Study of Efficacy and Safety. Respiratory Medicine, 124, 36-43. [Google Scholar] [CrossRef] [PubMed]
[20] 张晶鑫, 刘传和. 抗IgE抗体在儿童支气管哮喘中的应用及研究进展[J]. 临床药物治疗杂志, 2018, 16(6): 16-20.
[21] 马婷婷, 王向东, 陈艳蕾, 等. 奥马珠单抗治疗花粉症伴中重度哮喘患者的临床疗效及安全性研究[J]. 中国耳鼻咽喉头颈外科, 2018, 25(12): 675-678.
[22] Bhutani, M., Yang, W.H., Hebert, J., de Takacsy, F. and Stril, J.L. (2017) The Real World Effect of Omalizu-Mab Add on Therapy for Patients with Moderate to Severe Allergic Asthma: The ASTERIX Observational Study. PLOS ONE, 12, e183869. [Google Scholar] [CrossRef] [PubMed]
[23] Jahnz-Rózyk, K., Lis, J., Warchoł, M. and Kucharczyk, A. (2018) Clinical and Economic Impact of a One-Year Treatment with Omalizumab in Patients with Severe Allergic Asth-ma within a Drug Programme in Poland. BMC Pulmonary Medicine, 18, Article No. 48. [Google Scholar] [CrossRef] [PubMed]
[24] Busse, W.W., Humbert, M., Haselkom, T., et a1. (2020) Effect of Omalizumab on Lung Function and Eosinophil Levels in Adolescents with Moderateto-Severe Aller-Gicasthma. Annals of Allergy, Asthma & Immunology, 124, 190-196. [Google Scholar] [CrossRef] [PubMed]
[25] Licari, A., Castagnoli, R., Denicolo, C., et al. (2017) Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience. Current Respiratory Medicine Reviews, 13, 36-42. [Google Scholar] [CrossRef] 
[26] Solidoro, P., Patrucco, F., de Blasio, F., et al. (2019) Predictors of Reversible Airway Obstruction with Omalizumab in Severe Asthma: A Real-Life Study. Therapeutic Ad-vances in Respiratory Disease, 13. [Google Scholar] [CrossRef] [PubMed]
[27] Domingo, C., Pomares, X., Navarro, A., et al. (2018) A Step-Down Protocol for Omalizumab Treatment in Oralcorticosteroid-Dependent Allergic Asthma Patients. British Journal of Clinical Pharmacology, 84, 339-348. [Google Scholar] [CrossRef] [PubMed]
[28] Chipps, B.E., Lanier, B., Milgrom, H., et al. (2017) Omalizumab in Children with Uncontrolled Allergic Asthma: Review of Clinical Trial and Real-World Experience. Journal of Allergy and Clinical Immunology, 139, 1431-1444. [Google Scholar] [CrossRef] [PubMed]
[29] 林江涛. 抗IgE治疗变应性哮喘的长期有效性和安全性[J]. 中华结核和呼吸杂志, 2016, 39(9): 733-736.
[30] 沙莉, 刘传合. 生物制剂治疗支气管哮喘的研究进展[J]. 山东大学耳鼻喉眼学报, 2019, 33(1): 53-58.
[31] 徐艳华, 王菁兰, 王怡玮, 等. 33例141次奥马珠单抗治疗后不良反应回顾性研究[J]. 中华临床免疫和变态反应杂志, 2019, 13(6): 516-519.
[32] Humbert, M., Beasley, R., Ayres, J., et al. (2005) Benefits of Omalizumab as Add-on Therapy in Patients with Severe Persistent Asthma Who Are Inadequately Controlled Despite Best Available Therapy (GINA 2002 Step 4 Treatment): INNOVATE. Allergy, 60, 309-316.
[33] 戴然然, 周新. 奥马珠单抗治疗哮喘的临床应用进展[J]. 国际呼吸杂志, 2016, 36(13): 998-1001. [Google Scholar] [CrossRef] 
[34] Bousquet, J., Rabe, K., Humbert, M., et al. (2007) Predicting and Evaluating Response to Omalizumab in Patients with Severe Allergic Asthma. Respiratory Medicine, 101, 1483-1492. [Google Scholar] [CrossRef] [PubMed]
[35] 马晓伟. 奥马珠单抗联合布地奈德福莫特罗对IgE介导的哮喘患者临床疗效评价[D: [硕士学位论文]. 济南: 山东大学, 2021.
[36] Stokes, J. (2017) Anti-IgE Treat-ment for Disorders Other than Asthma. Frontiers in Medicine, 4, Article 152. [Google Scholar] [CrossRef] [PubMed]
[37] Zierau, L., Waisted, E.S., Thomsen, S.F., et al. (2017) Response to Omalizumab in Patients with Severe Allergic Asthma: A Real-Life Study. Respiratory Medicine, 131, 109-113. [Google Scholar] [CrossRef] [PubMed]
[38] Casale, T.B., Chipps, B.E., Rosén, K., et al. (2018) Response to Omalizumab Using Patient Enrichment Criteria from Trials of Novel Biologics in Asthma. Allergy, 73, 490-497. [Google Scholar] [CrossRef] [PubMed]
[39] 蔡慧, 墨玉清, 薛小敏, 等. 真实世界奥马珠单抗治疗中重度过敏性哮喘的疗效及安全性[J]. 中华临床免疫和变态反应杂志, 2019, 13(3): 199-204.
[40] Brooks, E.A., Massanari, M., Hanania, N.A. and Weiner, D.J. (2019) Cost-Effectiveness of Feactional Exhaled Nitri coxide (FeNO) Measurement in Predicting Response to Amalizumab in Asthma. ClinicoEconomics and Outcomes Research, 11, 301-307. [Google Scholar] [CrossRef] 
[41] 毛雅, 丁美, 梁慧玲, 等. 奥马珠单抗在过敏性哮喘中对哮喘和致敏的作用[J]. 医药导报, 2021, 40(12): 1684-1690.

为你推荐